We have developed an exciting virtual program that will permit delegates to learn about innovative new advances in cardiovascular disease and data science. The 2021 conference program will appeal to a wide audience as it features guideline updates, interactive workshops, poster presentations, as well as opportunities for networking and mutual learning. This format will allow key opinion leaders and trainees both to share the latest in cardiovascular research and treatments with health care practitioners and scientists across Canada.

The Toronto-Ottawa Heart Summit will take place virtually on:
September 24-25, 2021.

To register, please visit our website:

www.TorontoOttawaHeartSummit.com

PROGRAM DIRECTORS

Peter Liu, MD
Chief Scientific Officer
University of Ottawa Heart Institute

Michael Farkouh, MD
Peter Munk Chair in Multinational Trials
Director, Heart and Stroke Richard Lewar Centre of Excellence

PROGRAM AGENDA

	SPEAKER TALK TITLES

Day 1	Friday, September 24, 2021
	Trainee Poster Hall (Set up both days)
11:00	Welcome Remarks Drs. Peter Liu and Michael Farkouh
12:00	KEYNOTE PRESENTATION: Towards More Patient-Centered Cardiovascular Care: The Role of PROs in Clinical Trials, Clinical Care and Quality Assessment Dr. John Spertus
12:30	Discussion
	Session 1: Prevention Chair: Dr. Thais Coutinho
12:40	Cardiology Trainee Case Presentation
12:45	How to Prevent AF Including Cognitive Impairment Dr. TBA
1:00	Aspirin in Primary and Secondary Prevention: Indication and Dosing Dr. Guillaume Marquis-Gravel
1:15	Tai Chi and Cardiovascular Disease Dr. Gloria Yeh
1:30	Obesity Management Dr. TBA
1:45	Panel Discussion
	Health Break
	Session 2: Atrial Fibrillation Chair: Dr. Atul Verma
2:00	Cardiology Trainee Case Presentation
2:05	LAAOSIII: Left Atrial Occlusion Study III-LAA Occlusion During Cardiac Surgery Improves Outcomes Dr. Richard Whitlock
2:20	Atrial Ablation for Heart Failure Dr. Anthony Tang
2:35	Atrial Fibrillation & Renal Insufficiency Dr. Atul Verma
2:50	Panel Discussion
	Health Break
	Session 3: Intervention/ACS Chair: Drs. Jean-Francois Tanguay & Mina Madan
3:25	Cardiology Trainee Case Presentation
3:30	The PRAMI Trial to COMPLETE Dr. Shamir Mehta
3:45	PARADISE-MI Dr. Marc Pfeffer
4:00	Duration of DAPT Dr. TBA
4:15	TBD Dr. TBA
4:30	Panel Discussion
4:45	POSTER JUDGING/NETWORKING
6:00	Adjournment

Day 2	Saturday, September 25, 2021
	Trainee Poster Hall (Set up both days)
	THEME: Resolving 0ngoing Controversies in Cardiovascular Disease
8:30	Welcome Remarks Dr. Peter Liu and Michael Farkouh
	Session 4: Heart Failure Chairs: Dr. Javed Butler and Sharon Chih
8:40	Cardiology Trainee Case Presentation
8:45	HF Guidelines Update Dr. TBA
9:00	HFrEF: Novel sGC Stimulators Dr. Justin Ezekowitz
9:15	HFpEF EMPEROR Preserve Trial Dr. Javed Butler
9:30	Panel Discussion
	Session 5: ADVANCED Heart Failure Chair: Drs. Javed Butler and Sharon Chih
9:45	Cardiology Trainee Case Presentation
9:50	Shock Dr. Sharon Chih
10:05	Advanced HF Dr. TBA
10:20	GUIDE-IT Trial Dr. TBA
10:30	Panel Discussion
	Health Break
	Session 6: Valves Chair: Dr. Eric Horlick
10:55	Cardiology Trainee Case Presentation
11:00	TAVR Dr. Josep Rodes-Cabau
11:15	Mitral Clip-Determining Patient Eligibility and Success Dr. Anita Asgar
11:30	Tricuspid Valve—the Forgotten Valve Dr. Richard Cook
11:45	Panel Discussion
12:00	POSTER JUDGING/NETWORKING EVENT
	Health Break
	Session 7: Diabetes/Lipids Chair: Dr. Michael Farkouh
1:25	Cardiology Trainee Case Presentation
1:30	The Clinical Impact of SGLT 2 Inhibitors: CV Outcomes Trial Dr. Lawrence Leiter
1:45	GLP1 Receptor Antagonist Dr. TBA
2:00	MRA in Diabetic Diabetes (FIGARO-DKD) Dr. David Cherney
2:15	Beyond PCSK9 Dr. TBA
2:30	Lipid Guidelines Update Dr. TBA
2:45	Panel Discussion
3:00	Health Break
3:30	5 SELECTED POSTER PRESENTATIONS
	Session 8: Systemic Disease and the Heart Chair: Dr. Peter Liu
4:00	Cardiology Trainee Case Presentation
4:05	New Treatment Options for Management of Hyperkalemia in HF and CKD Dr. Phil McFarlane
4:20	Cardio-Oncology Dr. TBA
4:35	Amyloid Heart Disease-New Treatment Advances Dr. Mathew Maurer
4:50	Lipid Guidelines Update Dr. TBA
5:05	Panel Discussion
5:30	Closing Remarks & Adjournment

SYMPOSIUM OBJECTIVES

At the end of this symposium, participants should be able to:

Recognize the changing landscape in risk factor management and implement preventative cardiology recommendations and advocate health promotion
Review the growing incidence of AF in the population and the impact on cognitive function
Review the results of two doses of Aspirin in high-risk patients with CAD
Evaluate new treatment options in the management of obesity
Discuss non-pharmacological options for AF management
Examine the impact of LA appendage removal on CV outcomes
Review of AF in patients with renal insufficiency
Recognize the latest diagnostic and management strategies for patients with stable coronary artery disease
Discuss the impact of the late-breaking trial results on coronary artery disease
Review appropriate management of anticoagulant and antiplatelet therapies in patients with CAD
Discuss evidence from late-breaking trial results in management of patients with HFpEF and HFrEF
Review the latest CCS heart failure guidelines and apply practical strategies into daily clinical practice
Understand the trajectory of advance HF challenges and treatment options
Review the management of patients in cardiogenic shock
Understand the role and limitation of surgery and minimally invasive technologies, for aortic, mitral and tricuspid valves
Assess the implications of recent outcomes trials for the clinical management of patients with diabetes
Review the updated 2021 Guidelines on risk assessment and lipid management
Discuss insights into the potential effects on CV outcomes with use of MRA in patients with diabetic kidney disease
Review new treatment options in the management of hyperkalemia in patients with HF and CKD
Outline appropriate cardiac surveillance plans for patients receiving cancer therapies with potential cardiac toxicities
Describe cardiac Amyloidosis including specific types, cardiac features and management options

Why attend this symposium?

The overall goal of this symposium is to promote the exchange of existing knowledge from innovative cellular research, through translation, to foster dissemination and collaboration, leading to better cardiovascular outcomes.

Who should attend?

Cardiovascular specialists
Internists
Allied health professionals
Heart failure care teams
Cardiovascular Trainees, Residents and Fellows
Basic scientist interested in CV disease
Primary care providers

ACKNOWLEDGEMENT

Appreciation is expressed to the following in support of this program:

Grand Patrons: Boehringer Ingelheim-Lilly Partnership

Patrons: Bayer

Supporters: Bristol-Myers Squibb/Pfizer Partnership, AstraZeneca and HLS Therapeutics Inc.

CONTACT INFORMATION:

Alison Conley
University of Ottawa Heart Institute
40 Ruskin Street,
Ottawa, ON, K1Y 4W7
E-mail aconley@ottawaheart.ca

Shanas Mohamed, RN, BScN, CMP
E-mail shanasmailbox@gmail.com

This is an automatically generated email, Please do not reply. To unsubscribe click HERE